Advertisement

Journal of NeuroVirology

, Volume 22, Issue 3, pp 349–357 | Cite as

Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study

  • Adriana CarvalhalEmail author
  • M. John Gill
  • Scott L. Letendre
  • Anita Rachlis
  • Tsegaye Bekele
  • Janet Raboud
  • Ann Burchell
  • Sean B. Rourke
  • and the Centre for Brain Health in HIV/AIDS
Article

Abstract

Since the introduction of combination antiretroviral therapy (cART), the incidence of severe HIV-associated neurocognitive impairment has declined significantly, whereas the prevalence of the milder forms has increased. Studies suggest that better distribution of cART drugs into the CNS may be important in reducing viral replication in the CNS and in reducing HIV-related brain injury. Correlates of neuropsychological (NP) performance were determined in 417 participants of the Ontario HIV Treatment Cohort Study (OCS). All participants were on three cART drugs for at least 90 days prior to assessment. Multiple logistic and linear regression methods were used. Most participants were Caucasian men with mean age of 47 years. About two thirds had a nadir CD4+ T-cell count below 200 cells/μL and 92 % had an undetectable plasma HIV viral load. The median CNS penetration effectiveness (CPE) score was 7. Sixty percent of participants had neuropsychological impairment. Higher CPE values significantly correlated with lower prevalence of impairment in bivariate and multivariate analyses. In this cross-sectional analysis of HIV+ adults who had a low prevalence of comorbidities and were taking three-drug cART regimens, greater estimated distribution of cART drugs into the CNS was associated with better NP performance.

Keywords

HIV CPE Antiretroviral Neuropsychological impairment 

Notes

Acknowledgments

The Ontario HIV Treatment Network Cohort Study is funded by the Ontario Ministry of Health and Long-Term Care, OHTN Chair in Biostatistics. Public Health Ontario (PHO) Laboratories for providing the viral load testing. The views and conclusion presented here are not necessarily those of PHO. Preliminary results of this work was previously presented at the 19th Conference in Retrovirus and Opportunistic Infections CROI 2012 (Paper # 484)––Seattle, WA, USA.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. Albert SM, Marder K, Dooneief G, Bell K, Sano M, Todak G, Stern Y (1995) Neuropsychologic impairment in early HIV infection. A risk factor for work disability. Arch Neurol 52(5):525–530CrossRefPubMedGoogle Scholar
  2. Anstey KJ, von Sanden C, Salim A, O’Kearney R (2007) Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 166(4):367–378CrossRefPubMedGoogle Scholar
  3. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799CrossRefPubMedPubMedCentralGoogle Scholar
  4. Benedict RHB, Schretlen D, Groninger L, Brandt J (1998) Hopkins Verbal Learning Test–Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12:43–55Google Scholar
  5. Brandt J, Benedict RHB (2001) Hopkins Verbal Learning Test--Revised: Professional Manual. Psychological Assessment Resources, FloridaGoogle Scholar
  6. Bryant A, Ellis R, Umlauf A, Gouauz B, Soontornniyomkij V, Letendre S, Achim C, Masliah E, Grant I, Moore D (2015) Antiretroviral therapy reduces neurodegeneration in HIV infection. AIDS 29:323–330CrossRefPubMedPubMedCentralGoogle Scholar
  7. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26(3):307–319CrossRefPubMedGoogle Scholar
  8. Carvalhal A, Rourke S, Belmonte-Abreu P, Correa J, Goldani L (2006) Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active antiretroviral therapy. Infection 34:357–360CrossRefPubMedGoogle Scholar
  9. Chesney MA, Ickovics J, Chambers D, Gifford A, Neidig J, Zwickl B, Wu A, P. C. COMMITTEE and A. W. G. O. T. O. C. O. T. A. A. C. T. GROUP (2000) Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS care 12(3):255–266CrossRefPubMedGoogle Scholar
  10. Childs E, Lyles R, Selnes O, Chen B, Miller E, Cohen B, Becker J, Mellors J, McArthur J (1999) Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 52(3):607–607CrossRefPubMedGoogle Scholar
  11. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, Tamburrini E, Cauda R, De Luca A, Silveri MC (2011) Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76(16):1403–1409CrossRefPubMedGoogle Scholar
  12. Cysique LA, Waters EK, Brew BJ (2011) Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. (Research article)(Report). BMC Neurology 11:148CrossRefPubMedPubMedCentralGoogle Scholar
  13. Durvasula RS, Miller EN, Myers HF, Wyatt GE (2001) Predictors of neuropsychological performance in HIV positive women. J Clin Exp Neuropsychol 23:149–63Google Scholar
  14. Ellis RJ, Deutsch R, Heaton RK, Marcotte TD, McCutchan JA, Nelson JA, Abramson I, Thal LJ, Atkinson JH, Wallace MR, Grant I (1997) Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 54(4):416–424CrossRefPubMedGoogle Scholar
  15. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25(14):1747CrossRefPubMedGoogle Scholar
  16. Gibbie T, Mijch A, Ellen S, Hoy J, Hutchison C, Wright E, Chua P, Judd F (2006) Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Med 7(2):112–121CrossRefPubMedGoogle Scholar
  17. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (00392499) 42(9):2672–2713CrossRefGoogle Scholar
  18. Grant I, Sacktor N, McArthur J (2005) HIV neurocognitive disorders. In: Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S (eds) The neurology of AIDS (2nd edn). Oxford University Press, Oxford, pp 357–73Google Scholar
  19. Heaton RK, Kirson D, Velin RA, Grant I, a. t. H. Group (1994) The utility of clinical ratings for detecting early cognitive change in HIV infection. Neuropsychology of HIV infection. I. Grant and A. Martin. Oxford University Press, New York, pp 188–206Google Scholar
  20. Heaton RK, Marcotte TD, White DA, Ross D, Meredith K, Taylor MJ, Kaplan R, Grant I (1996) Nature and vocational significance of neuropsychological impairment associated with HIV infection. Clin Neuropsychol 10(1):1–14CrossRefGoogle Scholar
  21. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I (2004) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10(3):317–331CrossRefPubMedGoogle Scholar
  22. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology 75(23):2087–2096CrossRefPubMedPubMedCentralGoogle Scholar
  23. Hilsabeck R, Perry W, Hassanein T (2002) Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35(2):440–446Google Scholar
  24. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, Thrasher D, Goetz MB, Stefaniak M (2002) Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 59(12):1944–1950CrossRefPubMedPubMedCentralGoogle Scholar
  25. Kalmijn S, van Boxtel MP, Verschuren MW, Jolles J, Launer LJ (2002) Cigarette smoking and alcohol consumption in relation to cognitive performance in middle age. Am J Epidemiol 156(10):936–944CrossRefPubMedGoogle Scholar
  26. Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19(4):137–142PubMedPubMedCentralGoogle Scholar
  27. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65(1):65–70CrossRefPubMedPubMedCentralGoogle Scholar
  28. Letendre S, Ances B, Gibson S, Ellis RJ (2009) Neurologic complications of HIV disease and their treatment. Top HIV Med 15(2):32–39Google Scholar
  29. Letendre S, Ellis R, Ances B, McCutchan JA (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18(2):45–55PubMedGoogle Scholar
  30. Marcotte TD, Deutsch R, McCutchan JA, Moore DJ, Letendre S, Ellis RJ, Wallace MR, Heaton RK, Grant I (2003) Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol 60(10):1406CrossRefPubMedGoogle Scholar
  31. Marder K, Albert SM, McDermott M (1998) Prospective study of neurocognitive impairment in HIV (DANA cohort): Dementia and mortality outcomes. J Neurovirol 4Google Scholar
  32. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23(11):1359–1366CrossRefPubMedPubMedCentralGoogle Scholar
  33. Martin EM, Sullivan TS, Reed RA, Fletcher TA, Pitrak DL, Weddington W, Harrow M (2001) Auditory working memory in HIV-1 infection. J Int Neuropsychol Soc 7:20–6Google Scholar
  34. Mayeux R, Stern Y, Tang MX, Todak G, Marder K, Sano M, Richards M, Stein Z, Ehrhardt AA, Gorman JM (1993) Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 43(1):176–182CrossRefPubMedGoogle Scholar
  35. Morgan EE, Woods SP, Weber E, Dawson MS, Carey CL, Moran LM, Grant I (2009) HIV-associated episodic memory impairment: evidence of a possible differential deficit in source memory for complex visual stimuli. J Neuropsychiatry Clin Neurosci 21(2):189–198CrossRefPubMedPubMedCentralGoogle Scholar
  36. Mothobi NZ, Brew BJ (2012) Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis 25(1):4–9CrossRefPubMedGoogle Scholar
  37. Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, Pérez-Álvarez N, Moltó J, Gómez G, Clotet B (2008) Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 24(10):1301–1307CrossRefPubMedGoogle Scholar
  38. Norman MA, Moore DJ, Taylor M, Franklin D Jr, Cysique L, Ake C, Lazarretto D, Vaida F, Heaton R ( 2011) Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test–Revised, Brief Visuospatial Memory Test–Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol 33:793–804Google Scholar
  39. Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mossner R, Collier DA, Kuhn KU, Maier W, Wagner M, Kumari V (2010) Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology 35(7):1429–1439CrossRefPubMedPubMedCentralGoogle Scholar
  40. Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1(3):385–401CrossRefGoogle Scholar
  41. Rigbi A, Kanyas K, Yakir A, Greenbaum L, Pollak Y, Ben-Asher E, Lancet D, Kertzman S, Lerer B (2008) Why do young women smoke? V. Role of direct and interactive effects of nicotinic cholinergic receptor gene variation on neurocognitive function. Genes Brain Behav 7(2):164–172CrossRefPubMedGoogle Scholar
  42. Ritola K, Robertson K, Fiscus SA, Hall C, Swanstrom R (2005) Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 79(16):10830–10834CrossRefPubMedPubMedCentralGoogle Scholar
  43. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (London, England) 21(14):1915–1921CrossRefGoogle Scholar
  44. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ (2010) Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74(16):1260–1266CrossRefPubMedPubMedCentralGoogle Scholar
  45. Robertson K, Liner J, Meeker R (2012) Antiretroviral neurotoxicity. J Neurovirol 18(5):388–399CrossRefPubMedPubMedCentralGoogle Scholar
  46. Rourke SB, Gardner S, Burchell AN, Raboud J, Rueda S, Bayoumi AM, Loutfy M, Cooper C, Smieja M, Taylor D, DiPede T, Wobeser W, Major C, Waring V, Fisher M, Cairney J, Mittmann N, Salit IE, Crouzat F, Gough K, Ralph E, Sandre R, Kilby D, Rachlis A (2012) Cohort profile: the Ontario HIV Treatment Network Cohort Study (OCS). Int J Epidemiol 42:402–411CrossRefPubMedGoogle Scholar
  47. Ryan E, Morgello S, Isaacs K, Naseer M, Gerits P (2004) Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 62(6):957–962CrossRefPubMedPubMedCentralGoogle Scholar
  48. Saunders JB, Aasland OG, Babor TF, Fuente JR, Grant M (1993) Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II. Addiction 88(6):791–804CrossRefPubMedGoogle Scholar
  49. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (London, England) 25(3):357–365CrossRefGoogle Scholar
  50. Trepanier LL, Rourke SB, Bayoumi AM, Halman MH, Krzyzanowski S, Power C (2005) The impact of neuropsychological impairment and depression on health-related quality of life in HIV-infection. J Clin Exp Neuropsychol 27(1):1–15CrossRefPubMedGoogle Scholar
  51. Trites R (1989) Grooved pegboard test. Lafayette, Ind.: Lafayette InstrumentGoogle Scholar
  52. Tulsky DS (2003) Clinical interpretation of the WAIS-III and WMS-III. Academic Press, Amsterdam, BostonGoogle Scholar
  53. Underwood J, Robertson K, Winston A (2015) Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? AIDS 29:253–261CrossRefPubMedGoogle Scholar
  54. Vassallo M, Durrant J, Biscay V, Lebrum-Frenay C, Dunais B, Laffon M, Harvey-Langton A, Cottalorda J, Ticchioni M, Carsenti H, Pradier C, Dellamonica P (2014) Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? AIDS 28:493–501CrossRefPubMedGoogle Scholar
  55. Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, Power C (2010) Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology 75(13):1150–1158CrossRefPubMedPubMedCentralGoogle Scholar
  56. Wagner M, Schulze-Rauschenbach S, Petrovsky N, Brinkmeyer J, von der Goltz C, Grunder G, Spreckelmeyer KN, Wienker T, Diaz-Lacava A, Mobascher A, Dahmen N, Clepce M, Thuerauf N, Kiefer F, de Millas JW, Gallinat J, Winterer G (2013) Neurocognitive impairments in non-deprived smokers—results from a population-based multi-center study on smoking-related behavior. Addict Biol 18(4):752–761CrossRefPubMedGoogle Scholar
  57. Wechsler D (1981) Manual for the Wechsler Adult Intelligence Scale-Revised (WAIS-R). The Psychological Corporation, San Antonio, TXGoogle Scholar
  58. Wechsler D (1997) WAIS-III/WMS-III technical manual. The Psychological Corporation, San Antonio, TXGoogle Scholar
  59. Winterer G, Musso F, Konrad A, Vucurevic G, Stoeter P, Sander T, Gallinat J (2007) Association of attentional network function with exon 5 variations of the CHRNA4 gene. Hum Mol Genet 16(18):2165–2174CrossRefPubMedGoogle Scholar
  60. Winterer G, Mittelstrass K, Giegling I, Lamina C, Fehr C, Brenner H, Breitling LP, Nitz B, Raum E, Muller H, Gallinat J, Gal A, Heim K, Prokisch H, Meitinger T, Hartmann AM, Moller HJ, Gieger C, Wichmann HE, Illig T, Dahmen N, Rujescu D (2010) Risk gene variants for nicotine dependence in the CHRNA5-CHRNA3-CHRNB4 cluster are associated with cognitive performance. Am J Med Genet B Neuropsychiatr Genet 153b(8):1448–1458CrossRefPubMedGoogle Scholar
  61. Woods SP, Iudicello JE, Moran LM, Carey CL, Dawson MS, Grant I (2008) HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychology 22(1):110–117CrossRefPubMedPubMedCentralGoogle Scholar
  62. Yakir A, Rigbi A, Kanyas K, Pollak Y, Kahana G, Karni O, Eitan R, Kertzman S, Lerer B ( 2007) Why do young women smoke? III. Attention and impulsivity as neurocognitive predisposing factors. Eur Neuropsychopharmacol 17:339–51Google Scholar
  63. Zipursky A, Gogolishvili D, Rueda S, Atkinson M, Brunetta J, Carvalhal A, Collins E, McCombe J, Gill J, Arbess G, Marcotte J, Rourke S (2013) Evaluation of brief screening tools for neurocognitive tools for HAND. AIDS 27(15):2385–2401CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2015

Authors and Affiliations

  • Adriana Carvalhal
    • 1
    • 2
    Email author
  • M. John Gill
    • 3
  • Scott L. Letendre
    • 4
  • Anita Rachlis
    • 5
    • 6
  • Tsegaye Bekele
    • 7
  • Janet Raboud
    • 8
    • 9
  • Ann Burchell
    • 7
    • 9
  • Sean B. Rourke
    • 1
    • 2
    • 10
  • and the Centre for Brain Health in HIV/AIDS
  1. 1.Department of PsychiatryUniversity of TorontoTorontoCanada
  2. 2.Li Ka Shing Knowledge InstituteSt. Michael’s HospitalTorontoCanada
  3. 3.Department of MedicineUniversity of CalgaryCalgaryCanada
  4. 4.HIV Neurobehavioural Research Center and Antiretroviral Research CenterUniversity of California San DiegoSan DiegoUSA
  5. 5.Sunnybrook Health Sciences CenterTorontoCanada
  6. 6.Department of MedicineUniversity of TorontoTorontoCanada
  7. 7.The Ontario HIV Treatment NetworkTorontoCanada
  8. 8.Toronto General Research InstituteUniversity Health NetworkTorontoCanada
  9. 9.Dalla Lana School of Public HealthUniversity of TorontoTorontoCanada
  10. 10.The CIHR Centre for REACH in HIV/AIDS (Research Evidence into Action for Community Health)TorontoCanada

Personalised recommendations